vascular longevity doctrine: what to optimize now

public decision surface — 2026-04-12

tl;dr

lp(a) is the structural vascular tax. it matters a lot, but it is not the main cheap dial we can turn today.
the main things to tighten now are apoB / ldl-c, bp mean if it remains high-normal, bp variance / reactivity, and phenotype uncertainty via pwv and maybe later cac.
the main mistake would be to wait for future direct lp(a) drugs while leaving today’s atherogenic burden and vascular tone only half-optimized.
current pharma order still reads as: ezetimibe-first, then rosuvastatin low-dose if stronger lowering is wanted, then pcsk9 if targets or phenotype justify a deeper push.

lp(a) is confirmed twice: 49.76 mg/dL and 109 nmol/L.
apoB is decent but not “finished”: 0.71–0.77 g/L.
ldl-c is decent but not low enough to erase the lp(a) tax: about 2.8 mmol/L.
carotid phenotype is currently reassuring: imt = 0.8 mm, no plaque seen.
clean home bp is currently about 119.2 / 73.8, with morning mean 116.4 / 72.2 and evening mean 122.8 / 75.8.
the current bp story is not “clear home hypertension”; it is “normal-to-high-normal baseline with modest evening drift”.
the main missing layer is not another lipid theory. the main missing layer is pwv, and maybe later cac, to calibrate how hard prevention should actually be pushed.

fixed inherited risk should make the modifiable layer tighter, not make the system passive.
apoB is the main modifiable freight.
lp(a) is the multiplier that changes how “good enough” the rest of the panel should be read.
bp is not just a threshold problem. it is a vascular-tone and recovery-economics problem.
imaging sharpens prevention intensity better than more genome mysticism.
strong fitness does not cancel structural vascular risk.

apoB / ldl-c burden. this is the cleanest modifiable atherogenic cargo layer.
bp mean, if the clean series keeps living in high-normal rather than settling lower.
bp variance. longevity is not just about one mean; noisy pressure is part of the cost.
bp reactivity + recovery. the question is how much the vascular system spikes under perturbation and how fast it comes back.
uncertainty. pwv and maybe cac matter because they tell us whether the phenotype already looks older than the bloodwork.

not repeated lp(a) measurements. the doctrine already knows the answer: it is persistently elevated.
not theoretical fear from unresolved genetics. that layer is cleaner now than before.
not “future drug anticipation” as a substitute for current governance.

the right formula is:

low mean + low variance + low reactivity + fast recovery

that means the useful questions are:

ezetimibe-first still looks like the cleanest first move if the goal is modest but real tightening of ldl/apoB.
rosuvastatin low-dose is more defensible than before because abcg2 ambiguity was cleaned up.
rosuvastatin is still not perfectly frictionless because slco1b1 keeps statin entry less than neutral.
pcsk9 remains the stronger move if deeper ldl-c lowering and a bonus lp(a) drop are worth the added medical weight.
niacin is still not the elegant default path.

future lp(a) therapy may remove one major tax. it does not make sloppy vascular governance smart.

the visual system should always split into four layers:

fixed tax: lp(a).
modifiable burden: apoB, ldl-c, bp mean, bp variance, bp reactivity.
phenotype calibration: imt, plaque, pwv, cac.
decision ladder: maintain, tighten modestly, push harder, or wait for future tools without using that as an excuse.

do not wait for a future magical lp(a) fix while leaving today’s atherogenic burden and vascular tone under-optimized.

treat lp(a) as persistent context, not as a weekly lab.
tighten apoB / ldl-c cleanly.
keep building the home bp read as mean + variance + reactivity + recovery.
add pwv, and maybe later cac, if prevention intensity still feels ambiguous.
escalate pharma only after the phenotype and the clean series sharpen the choice.